deltatrials
Terminated PHASE2 INTERVENTIONAL 1-arm NCT01531712

Study of Neoadjuvant Treatment in Patients With Pancreatic Cancer That is Potentially Resectable

Phase II Study of Neoadjuvant Treatment With Gemcitabine, Tarceva and Oxaliplatin Followed by Chemotherapy With Tarceva and Gemcitabine in Patients With Pancreas Adenocarcinoma With Borderline Resectability.

Sponsor: Institut Català d'Oncologia

Conditions Pancreatic Cancer
Interventions Gemcitabine Oxaliplatin Radiotherapy Tarceva
Updated 7 times since 2017 Last updated: Aug 28, 2017 Started: Feb 10, 2011 Primary completion: Dec 31, 2012 Completion: Dec 31, 2012
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Due to a low recruitment rate since start of recruitment period.

Other Pancreatic Cancer trials with similar outcome

Browse all Pancreatic Cancer trials

Listed as NCT01531712, this PHASE2 trial focuses on Pancreatic Cancer and remains terminated or withdrawn. Sponsored by Institut Català d'Oncologia, it has been updated 7 times since 2011, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Sep 2017 · 8 months · monthly snapshotTerminated~Sep 2017 – ~Jun 2018 · 9 months · monthly snapshotTerminated~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotTerminated~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotTerminated~Sep 2025 – present · 10 months · monthly snapshotTerminated

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  4. Jan 2021 — Jul 2024 [monthly]

    Terminated PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE2

▶ Show 2 earlier versions

  1. Sep 2017 — Jun 2018 [monthly]

    Terminated PHASE2

  2. Jan 2017 — Sep 2017 [monthly]

    Terminated PHASE2

    First recorded

Feb 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Institut Català d'Oncologia
Data source: Institut Català d'Oncologia

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations